XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net loss $ (16,772,393) $ (5,548,873)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation expense 3,444
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 6,045,455 39,344
Stock-based compensation expense - PAVmed Inc. 2014 Equity Plan 111,084 9,750
Changes in operating assets and liabilities:    
Accounts receivable (200,000)
Prepaid expenses and other assets (954,540) (879,370)
Accounts payable 780,561 622,180
Accrued expenses and other liabilities 135,877 359,534
Accrued CWRU License Agreement Fee (222,553)
Due To: PAVmed Inc. - operating expenses paid on-behalf-of Lucid Diagnostics Inc. 178,309 334,425
Due To: PAVmed Inc. - Management Services Agreement Fee 2,510,000 1,110,000
Due To: PAVmed Inc. - Interest Expense - Senior Unsecured Promissory Note 593,813
Net cash flows used in operating activities (7,790,943) (3,953,010)
Cash flows from investing activities    
Purchase of equipment (37,886)
Net cash flows used in investing activities (37,886)
Cash flows from financing activities    
Proceeds – exercise of stock options 4,999
Proceeds – Due To: PAVmed Inc. - working capital cash advances 7,738,910 3,978,500
Net cash flows provided by financing activities 7,738,910 3,983,499
Net increase (decrease) in cash (89,919) 30,489
Cash, beginning of period 111,255 156,404
Cash, end of period $ 21,336 $ 186,893